Unlearn Appoints Alex Lang, Ph.D. as Vice President Technology

SAN FRANCISCO–(BUSINESS WIRE)–Unlearn®, the only artificial intelligence (AI) company developing predictive digital twins to conduct smaller, faster clinical trials, today announced that Alex Lang, Ph.D. was appointed Vice President, Technology. In this role, he will lead the company’s data science, modeling and platform teams responsible for delivering innovative solutions for Unlearn’s pharma and biotech partners to conduct more efficient clinical trials that help bring new… make treatments available sooner.

“We are delighted to welcome Alex to the Unlearn team. A physicist by training, he brings extensive hands-on industry experience in machine learning and leading teams that design and deliver mission-critical AI-based commercial solutions,” said Charles Fisher, Ph.D., founder and CEO of Unlearn. “On behalf of the entire team, we look forward to Alex’s leadership as we continue to build Unlearn’s capabilities as a leader and innovator of AI in medicine.”

Alex comes to Unlearn from Cruise, a well-known driverless car company, where he was Senior Manager, Perception. In this role, Alex led multiple teams of engineers to successfully solve perception problems for autonomous vehicles. Prior to Cruise, he led software and machine learning engineering teams at Motional as Director, Perception and Prediction. Earlier in his career, Alex was a postdoctoral fellow in the Computational Neurobiology Laboratory of Dr. Terrence Sejnowski at the Salk Institute, where he researched deep learning applications in computational neuroscience. Alex earned a Ph.D. in Physics from Boston University and BA in Physics and Mathematics from the University of Wisconsin and author of numerous peer-reviewed publications in the fields of physics, biology and machine learning.

“I love working with passionate people to turn seemingly unsolvable problems into real solutions that can have a positive impact on the world,” said Alex. “Unlearn is developing advanced AI applications that will revolutionize the future of medicine and will one day eliminate the need for human experimentation to bring new treatments to market.”

About unlearning

Founded in 2017, Unlearn.AI brings together a world-class team of pharma, physics, machine learning and business experts who share a vision of groundbreaking AI to eliminate trial and error in medicine. Unlearn is the only company that creates TwinRCTsTM, which combine AI, prognostic digital twins and novel statistical methods to conduct clinical trials that require fewer patients in the control arm. Unlearn’s technology is used by leading global pharmaceutical companies including Merck KGaA, Darmstadt, Germany and has been published in conference abstracts and scientific journals, including Scientific Reports – Nature and The International Journal of Biostatistics. The European Medicines Agency qualifies Unlearn’s PROCOVA™ process, which provides the regulatory framework for the application of TwinRCTs to phase 2 and 3 clinical trials. For more information, please visit https://www.unlearn.ai or follow us @UnlearnAI on Twitter, @unlearn-ai on LinkedIn.


Leave a Reply

Your email address will not be published. Required fields are marked *